Autolus Therapeutics Receives Prix Galien UK Award

LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product.

GlobeNewsWire • 20 hours ago

Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUTL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Investment Research • Jun 10, 2026

Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?

Autolus Therapeutics PLC Sponsored ADR (AUTL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AUTL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Zacks Investment Research • Jun 1, 2026

Autolus Therapeutics to Participate in Upcoming Investor Conferences

LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.

GlobeNewsWire • May 27, 2026

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.

GlobeNewsWire • May 21, 2026

Autolus Therapeutics Q1 Earnings Call Highlights

Autolus Therapeutics NASDAQ: AUTL reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue guidance for the cell therapy.

MarketBeat • May 14, 2026

Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript

Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 15, 2026

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positive gross margin for the acute lymphoblastic leukemia (ALL) business Cost reduction initiative to drive gross profit margin improvement and path to profitability for the ALL business underway Obe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS) Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON and GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announces its operational and financial results for the first quarter ended March 31, 2026.

GlobeNewsWire • May 14, 2026

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its first quarter 2026 financial results and operational highlights before open of U.S. markets on Thursday, May 14, 2026.

GlobeNewsWire • May 5, 2026

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Initiative focused on driving gross profit margin and path to profitability for the ALL business Company will reduce headcount by approximately 13% while doubling manufacturing of products for commercial and clinical trial patients in 2026 Autolus reiterates full year 2026 AUCATZYL® net product revenue of $120 million to $135 million, up from $74 million in 2025, as well as an anticipated shift to positive gross margin in 2026 Clinical development programs are on track and include CATULUS, a pivotal Phase 2 trial in pediatric relapsed/refractory acute lymphoblastic leukemia; LUMINA, a pivotal Phase 2 trial in lupus nephritis; and BOBCAT, an exploratory Phase 1 trial in progressive multiple sclerosis LONDON and GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced a strategic initiative and plan to improve operational efficiency and reduce operating expenses.

GlobeNewsWire • Apr 29, 2026